Logo

Pharsight, Organon Pen Trial-Modeling Collaboration

Aug 20, 2002

NEW YORK, Aug. 20 - Pharsight today said that Organon will use its clinical trial-modeling -simulation technology to help it develop better clinical trials and improve its drug-development process.

 

The deal, an extension of an existing collaboration, may extend further if both sides are happy with the outcome of this part.

 

Click here for more information.

Breaking News
The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.